Compare HSBC Holdings plc (HSBC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs GeneDx Holdings Corp — how do they compare? HSBC Holdings plc trades at $92.98 (market cap $311.92B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: HSBC Holdings plc is far larger — about 154.4× GeneDx Holdings Corp's market cap, and HSBC Holdings plc pays a 4.05% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 36 Days and GeneDx Holdings Corp for 19 Days on average.
| HSBC | WGS | |
|---|---|---|
Market Cap | $311.92B | $2.02B |
Volume | 3,546,658 | 734,640 |
Sector | Financials | Health |
52-Week High | $107.86 | $167.51 |
52-Week Low | $65.67 | $34.51 |
Typical Hold Time | 36 Days | 19 Days |
Enterprise Value | $222.19B | $2.05B |
Dividend Yield | 4.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $92.61, down 1.17% over the past 24 hours, with technical indicators signaling a bearish trend. The company reported strong profitability with a net income margin of 34.54% and a P/E ratio of 13.23, reflecting reasonable valuation. Recent developments include expansion in technology banking and wealth management services, alongside strategic exits from non-core markets like Germany.
The outlook for HSBC is mixed; growth in wealth management and Asia presents opportunities, but bearish technicals and CFO transition in 2027 pose risks. Analyst sentiment is cautious with a majority hold rating, emphasizing the need for execution on strategic priorities to drive shareholder value amid global economic uncertainties.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
